Mylan nabs Indian OK for Agila buy; Sanofi chief takes over at EFPIA;

 @FiercePharma: Sanofi, Novartis, Glaxo said to be circling India's Elder Pharma. Private equity, too. News | Follow @FiercePharma

 @EricPFierce: Ranbaxy gets some support from India's Supreme Court as company faces down concerns there. Item | Follow @EricPFierce

 @CarlyHFierce: Proxy fight heating up at Vivus...First Manhattan announces search for new CEO candidates. Report | Follow @CarlyHFierce

> Mylan ($MYL) won Indian regulatory approval for its buyout of the injectables drugmaker Agila Specialties. Report

> Sanofi ($SNY) CEO Christopher Viebacher has taken over as president of the European Federation of Pharmaceutical Industries and Associations (EFPIA). Report

> Avanir Pharmaceuticals ($AVNR) won approval from the European Commission for its drug Nuedexta, a treatment for pseudobulbar affect, a condition characterized by extraordinary emotional outbursts. Report

> Hungary's Richter snapped up a manufacturing and marketing license to Acrux's estradiol spray for menopause symptoms in a deal worth up to $3.6 million. Report

> Aspirin's benefit in thwarting colon cancer doesn't extend to tumors with a mutation in the BRAF gene, a study found. Report

> Taking medicines containing caffeine was linked to a double or even triple risk of stroke, a new study found. Report

Medical Device News

 @FierceMedDev: Activaero readies for hoped-for EU launch of its first drug/device treatment. Editor's corner | Follow @FierceMedDev

 @DamianFierce: Delcath is axing 20% of its workforce after the FDA frowned upon its cancer-treating device. News | Follow @DamianFierce

> Thermo pours $9.5M into Chinese R&D shop. More

> Navidea raises $25M to market Lymphoseek. Item

> Intuitive hit with FDA warning over da Vinci reports. Story

> NanoString craves $54M in scaled-back IPO. Report

Biotech News

 @FierceBiotech: Where were the breakthrough drugs for diabetes at ADA 2013? Editor's corner | Follow @FierceBiotech

 @JohnCFierce: Have to wonder how PTC's IPO will come out as questions are raised about its lead obsession, um, program. Article | Follow @JohnCFierce

 @RyanMFierce: Verastem launching a PhI for second FAK inhibitor in pipeline. | Follow @RyanMFierce

 @EmilyMFierce: And back to biotech... Genetic biomarkers could help tailor breast cancer therapies. Article | Follow @EmilyMFierce

> Roche, AstraZeneca join forces on precompetitive R&D initiative. More

> Delcath slashes U.S. staff by 20% after FDA-panel disaster. Story

Biomarkers News

> Arizona's TGen and Ventana Medical Systems partner to find cancer biomarkers. News

> New diagnostic IDs patients unlikely to benefit from chemoradiation. Item

> Traumatic brain injury biomarker company raises $6M for diagnostic. Item

> HPV antibodies point researchers to high risk for oral cancer. Story

> Brain scan may provide biomarker guideposts to ideal depression treatment. Article

Drug Delivery News

 @MichaelGFierce: Trending right now at FierceDrugDelivery: Insulin delivery devices at ADA 2013. Roundup | Follow @MichaelGFierce

> Acorda reports positive data for epilepsy nasal spray. Item

> Alnylam posts positive preclinical RNAi delivery results for fatal conditions. Article

> Microbubbles for imaging offer targeted drug-delivery approach. More

> Peptide-coated nano-gold shows cancer-fighting promise. Report

And Finally... Expensive running shoes don't prevent injuries, a study found. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.